Skip to main content
logo
Ernexa Therapeutics Inc. (ERNA)
NASDAQ: ERNA · Real-Time Price · USD
8.00
-1.12 (-12.28%)
Jun 2, 2026, 4:00 PM EDT - Market closed

Ernexa Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
--0.580.07--
Revenue Growth (YoY)
--755.88%---
Cost of Revenue
--0.10.24--
Gross Profit
--0.49-0.17--
Selling, General & Admin
5.375.1613.1314.5916.8414.72
Research & Development
4.764.164.66.3816.3893.24
Other Operating Expenses
2.04-1.58--5.77
Total Operating Expenses
12.189.3219.3120.9733.22113.73
Operating Income
-12.18-9.32-15.67-21.14-33.22-113.73
Interest Income
0.040.080.25---
Interest Expense
-0.036.75---
Other Non-Operating Income (Expense)
0.22-4.87-22.33---9.65
Total Non-Operating Income (Expense)
0.27-4.76-15.33---9.65
Pretax Income
-11.48-14.13-44.51-21.67-24.53-122.48
Provision for Income Taxes
0.090.05-0.030-0.05-0.06
Net Income
-18.49-14.1-44.56-21.68-24.6-122.56
Net Income Attributable to Preferred Dividends
-0.02-0.02-0.02-0.02-0.02-0.02
Net Income to Common
-18.49-14.1-44.56-21.68-24.6-122.56
Shares Outstanding (Basic)
000000
Shares Outstanding (Diluted)
000000
Shares Change (YoY)
507.15%593.08%157.06%74.04%40.92%146.19%
EPS (Basic)
-26.20-56.00-1224.00-1531.25-3022.50-21228.80
EPS (Diluted)
-26.20-56.00-1224.00-1531.25-3022.50-21228.80
Shares Outstanding
1.170.310.140.010.010.01
Free Cash Flow
-7.26-7.05-16.21-20.43-21.27-23.64
Free Cash Flow Per Share
-17.50-27.96-445.19-1442.58-2614.68-4095.03
Gross Margin
--83.51%-247.06%--
Operating Margin
---2693.13%-31080.90%--
Profit Margin
---7652.75%-31864.70%--
FCF Margin
---2784.36%-30039.70%--
EBITDA
-12.12-9.25-15.54-21.05-33.06-113.62
EBITDA Margin
---2669.24%-30957.40%--
EBIT
-12.18-9.32-15.67-21.14-33.22-113.73
EBIT Margin
---2693.13%-31080.90%--
Effective Tax Rate
-0.81%-0.32%0.07%-0.01%0.18%0.05%
SEC Filings: 10-K · 10-Q